期刊文献+

己酮可可碱对慢性充血性心力衰竭患者CD4^+辅助性T淋巴细胞功能的调节

Regulatory effects of pemoxifylline on function of CD4^+ Th cells in patients with chronic congestive cardiac failure
暂未订购
导出
摘要 目的探讨己酮可可碱(PTX)对慢性充血性心力衰竭(CHF)患者外周血CD4^+辅助性T淋巴细胞(Th细胞)亚群平衡偏移的调节及意义。方法采用流式细胞分析法测定健康者(对照组,10例)、CHF患者(50例)加PTX(PTX组)及不加PTX(非PTX组)时的CD4^+Th细胞胞内细胞因子γ干扰素(IFN-γ)和白细胞介素(IL)-10。结果3组间IFN-γ、IL-10和IL-10/IFN-γ的差异均有统计学意义(F值分别=95.79、135.34和107.00,P值均<0.01)。PTX和非PTX组的IFN-γ均显著高于对照组(P<0.01),前两组间的差异也有统计学意义(P<0.01)。对照组的IL-10、IL-10/IFN-γ明显高于PTX和非PTX组(P值均<0.01),后两组间的差异也有统计学意义(P<0.01)。结论CHF患者存在CD4^+Th细胞亚群平衡偏移,而PTX可逆转充血性心力衰竭Th1/Th2细胞的失衡,从而调节CD4^+Th细胞的功能。 Objective To investigate the effect of pemoxifylline(PTX) on the imbalance of Th1/Th2 sub group in patients with chronic heart failure. Methods Peripheral blood cells were collected from 10 healthy subjects and 50 PTX-treated and non-treated patients with chronic heart failure. The levels of IFN-γ and IL-10 in CD4^+ Th cells were determined by 3-color flow cytometry after stimulation with phorbol myristate acetate(PMA) and ionomycin. Results The levels of IFN-γ, IL-10 and the ratio of IL-10/IFN-γ were significantly different between the 3 groups(all P 〈 0.01). The level of IFN-γ in CHF patients was significantly higher than that in healthy controls; there was also significant difference between PTX-treated and non-treated groups (P 〈 0.01). The levels of IL-10 and the ratio of IL-10/IFN-γ in the control group were significantly higher than those of the PTX-treated and non-treated groups(both P 〈 0.01) ; there was also significant difference between PTX-treated and non-treated groups (P〈0.01). Condusion Th1/Th2 functional imbalance exists in patients with CHF. PTX can correct the imbalance and subsequently regulate the function of CD4^+ Th cells. (Shanghai Med J, 2007, 30:852-854)
出处 《上海医学》 CAS CSCD 北大核心 2007年第11期852-854,共3页 Shanghai Medical Journal
关键词 己酮可可碱 慢性充血性心力衰竭 T淋巴细胞 Γ干扰素 白细胞介素-10 Pentoxifylline Chronic congestive heart faiure T-lymphocytes Interferon gamma Interleukin- 10
  • 相关文献

参考文献12

  • 1Buja LM,Willerson JT.Role of inflammation in coronary plaque disruption.Circulation,1994,89:503-505.
  • 2Yamaoka-Tojo M,Tojo T,Inomata T,et al.Circulating levels of interleukin 18 reflect etiologies of heart failure:Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advancedheart failure.J Card Fail,2002,8:21-27.
  • 3McElhaney JE,Herre JM,Lawson ML,et al.Effect of congestive heart failure on humoral and ex vivo cellular immune responses to influenza vaccination in older adults.Vaccine,2004,22:681-688.
  • 4Gullestad L,Aass H,Fjeld JG,et al.Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure.Circulation,2001,103:220-225.
  • 5Benbernou N,Esnault S,Shin HC,et al.Differential regulation of IFN-gamma,IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway.Immunology,1997,91:361-368.
  • 6Sliwa K,Woodiwiss A,Candy G,et al.Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.Am J Cardiol,2002,90:1118-1122.
  • 7Sliwa K,Woodiwiss A,Kone VN,et al.Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline:results of a randomized study.Circulation,2004,109:750-755.
  • 8Colucci WS.Apoptosis in the heart.N Engl J Med,1996,335:1224-1226.
  • 9Krown KA,Page MT,Nguyen C,et al.Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes.Involvement of the sphingolipid signaling cascade in cardiac cell death.J Clin Invest,1996,98:2854-2865.
  • 10Balligand JL,Ungureanu-Longrois D,Simmons WW,et al.Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1 beta and IFN-gamma.Am J Physiol,1995,268:H1293-H1303.

二级参考文献8

  • 1Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept(Enbrel) in patients with advanced heart failure[J]. Circulation,2001,103:1044-1047.
  • 2Fichtlscherer S, Rossig L, Breuer S, et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure[J]. Circulation, 2001,104 : 3023-3025.
  • 3Coletta AP, Clark AL, Banarjee P, et al. Clinical trials update:RENEWAL (RENAISSANCE and RECOVER) and ATTACH[J]. Eur Heart Fail, 2002,4:559-561.
  • 4Chung ES, Packer M, Lo KM, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure [J]. Circulation, 2003, 107:3133-3140.
  • 5Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of results of RECOVER, RENAISSANCE,RENEWAL and ATTACH [J]. Int Cardiol, 2002,86:123-130.
  • 6Staudt A, Landsberger M, Stault Y, et al. Cytokines-eauses,players or bystanders in heart failure [J]. Herz, 2002,27: 691-698.
  • 7Skudicky D, Bergemann A, Sliwa K. Beneficial effects of pentoxifyline in patients with idiopathic dilated cardomyopathy treated with angiotensin-converting enzyme inhibiors and carvedilol. Results of a randomized study[J]. Circulation, 2001,103 : 1083-1088.
  • 8Sliwa K, Woodiniss A, Kone VN. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline:results of a randomized study[J]. Circulation, 2004, 109:750-755.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部